Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group
Autor: | N. J. Petrelli, Y. Z. Patt, L Hammershaimb, Frederick L. Moffat, F. S. Whaley, C. M. Pinsky, David M. Goldenberg |
---|---|
Rok vydání: | 1996 |
Předmět: |
Male
Cancer Research medicine.medical_specialty chemistry.chemical_element Rectum Technetium Scintigraphy Sensitivity and Specificity Immunoscintigraphy Immunoglobulin Fab Fragments Carcinoembryonic antigen Predictive Value of Tests Carcinoma medicine Humans Prospective Studies Sodium Pertechnetate Tc 99m biology medicine.diagnostic_test Rectal Neoplasms business.industry Arcitumomab Antibodies Monoclonal Middle Aged medicine.disease United States Carcinoembryonic Antigen Surgery medicine.anatomical_structure Radioimmunodetection Oncology chemistry Colonic Neoplasms biology.protein business Technetium-99m |
Zdroj: | Journal of Clinical Oncology. 14:2295-2305 |
ISSN: | 1527-7755 0732-183X |
Popis: | PURPOSE To assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. METHODS CEA-Scan, an anti-carcinoembryonic antigen (CEA) Fab antibody fragment labeled with technetium-99m-pertechnetate (99mTc), was injected intravenously (IV), and external scintigraphy was performed 2 to 5 and 18 to 24 hours later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. RESULTS The sensitivity of CEA-Scan was superior to that of CDM in the extrahepatic abdomen (55% v 32%; P = .007) and pelvis (69% v 48%; P = .005), and CEA-Scan findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive (98%) compared with each alone (68% to 70%), potentially obviating the need for histologic confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61% v 33%). Potential clinical benefit from CEA-Scan was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of 19 assessable patients after two injections. CONCLUSION CEA-Scan affords high-quality, same-day imaging, uses an inexpensive and readily available radio-nuclide, adds clinically significant information in assessing extent and location of disease in colorectal cancer patients, and only rarely induces a HAMA response. |
Databáze: | OpenAIRE |
Externí odkaz: |